The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
16 08 2022
Historique:
received: 19 10 2021
revised: 03 05 2022
accepted: 14 06 2022
pubmed: 23 6 2022
medline: 18 8 2022
entrez: 22 6 2022
Statut: ppublish

Résumé

African-American (AA) men are more likely to be diagnosed with and die from prostate cancer than European American (EA) men. Despite the central role of the androgen receptor (AR) transcription factor in prostate cancer, little is known about the contribution of epigenetics to observed racial disparities. We performed AR chromatin immunoprecipitation sequencing on primary prostate tumors from AA and EA men, finding that sites with greater AR binding intensity in AA relative to EA prostate cancer are enriched for lipid metabolism and immune response genes. Integration with transcriptomic and metabolomic data demonstrated coinciding upregulation of lipid metabolism gene expression and increased lipid levels in AA prostate cancer. In a metastatic prostate cancer cohort, upregulated lipid metabolism associated with poor prognosis. These findings offer the first insights into ancestry-specific differences in the prostate cancer AR cistrome. The data suggest a model whereby increased androgen signaling may contribute to higher levels of lipid metabolism, immune response, and cytokine signaling in AA prostate tumors. Given the association of upregulated lipogenesis with prostate cancer progression, our study provides a plausible biological explanation for the higher incidence and aggressiveness of prostate cancer observed in AA men. With immunotherapies and inhibitors of metabolic enzymes in clinical development, the altered lipid metabolism and immune response in African-American men provides potential therapeutic opportunities to attenuate racial disparities in prostate cancer.

Identifiants

pubmed: 35731919
pii: 705059
doi: 10.1158/0008-5472.CAN-21-3552
pmc: PMC9379363
mid: NIHMS1820275
doi:

Substances chimiques

Receptors, Androgen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2848-2859

Subventions

Organisme : NCI NIH HHS
ID : U54 CA233223
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA251560
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM136554
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009172
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA131945
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008231
Pays : United States

Informations de copyright

©2022 The Authors; Published by the American Association for Cancer Research.

Références

Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
N Engl J Med. 2012 Jan 12;366(2):141-9
pubmed: 22236224
Cell Metab. 2014 Mar 4;19(3):393-406
pubmed: 24606897
Lipids Health Dis. 2019 Nov 3;18(1):189
pubmed: 31677641
Nat Genet. 2020 Aug;52(8):790-799
pubmed: 32690948
J Urol. 2000 Jan;163(1):137-42
pubmed: 10604331
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640
pubmed: 30578319
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Pharmacogenomics. 2016 Jul;17(10):1129-1143
pubmed: 27359067
Clin Cancer Res. 2021 Jan 1;27(1):320-329
pubmed: 33037017
Commun Biol. 2021 Jun 3;4(1):670
pubmed: 34083737
Genomics. 2019 Jan;111(1):10-16
pubmed: 26902887
Cancer Res. 2008 Feb 1;68(3):927-36
pubmed: 18245496
Bioinformatics. 2013 Jun 1;29(11):1399-406
pubmed: 23539302
Genome Biol. 2012 Oct 03;13(10):R88
pubmed: 23034120
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Cancer Res. 2009 Apr 1;69(7):2734-8
pubmed: 19293179
Nat Commun. 2018 Aug 28;9(1):3375
pubmed: 30154441
Oncotarget. 2021 Jul 20;12(15):1457-1469
pubmed: 34316327
Nat Genet. 2016 Aug;48(8):965-969
pubmed: 27376236
Oncogene. 2018 Feb 8;37(6):710-721
pubmed: 29059155
Urology. 1995 Jan;45(1):81-6
pubmed: 7817483
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526
pubmed: 32111923
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Natl Cancer Inst. 2020 Jun 1;112(6):562-573
pubmed: 32145020
Nat Protoc. 2012 Mar 01;7(3):562-78
pubmed: 22383036
Int J Cancer. 2010 Jan 15;126(2):416-25
pubmed: 19621387
Nucleic Acids Res. 2019 Jul 2;47(W1):W206-W211
pubmed: 31053864
BMC Bioinformatics. 2018 Apr 12;19(1):135
pubmed: 29649993
PLoS Genet. 2020 Feb 14;16(2):e1008641
pubmed: 32059012
Int J Cancer. 2014 Jan 1;134(1):81-91
pubmed: 23754304
Bioinformatics. 2012 Oct 1;28(19):2520-2
pubmed: 22908215
Nat Rev Immunol. 2019 Jul;19(7):417-432
pubmed: 30918351
Oncogene. 2020 Apr;39(18):3666-3679
pubmed: 32139877
Prostate. 2019 Aug;79(11):1274-1283
pubmed: 31111520
Nat Genet. 2021 Jan;53(1):65-75
pubmed: 33398198
Cancers (Basel). 2020 Nov 11;12(11):
pubmed: 33187317
Ethn Dis. 2000 Winter;10(1):69-75
pubmed: 10764132
Mol Cancer Res. 2021 Mar;19(3):475-484
pubmed: 33168599
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
J Pathol. 2021 Mar;253(3):292-303
pubmed: 33166087
Mol Cancer Res. 2017 Apr;15(4):439-447
pubmed: 28074002
Nat Genet. 2015 Nov;47(11):1346-51
pubmed: 26457646
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Nat Rev Urol. 2020 Apr;17(4):214-231
pubmed: 32112053
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
PLoS One. 2014 Jan 22;9(1):e87204
pubmed: 24466341
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cancer Res. 2021 Nov 1;81(21):5477-5490
pubmed: 34301759
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Metabolomics. 2018 Sep 20;14(10):128
pubmed: 30830398
Nat Biotechnol. 2010 May;28(5):495-501
pubmed: 20436461
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14068-73
pubmed: 16945910
Clin Cancer Res. 2010 Jul 15;16(14):3539-47
pubmed: 20606036
Bioinformatics. 2017 Aug 01;33(15):2381-2383
pubmed: 28369316
J Urol. 2003 Sep;170(3):990-3
pubmed: 12913756
N Engl J Med. 2020 Sep 10;383(11):1083-1085
pubmed: 32905685
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):891-7
pubmed: 23515145
Eur J Cancer. 2018 Mar;91:107-115
pubmed: 29413967
Nature. 2019 Jul;571(7765):413-418
pubmed: 31243372
Epigenetics. 2015;10(4):319-28
pubmed: 25864488
Elife. 2017 Jan 03;6:
pubmed: 28044981

Auteurs

Jacob E Berchuck (JE)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Elio Adib (E)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.

Sarah Abou Alaiwi (S)

Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Amit K Dash (AK)

Department of Medicine, Baylor College of Medicine, Houston, Texas.

Jin Na Shin (JN)

Department of Medicine, Baylor College of Medicine, Houston, Texas.

Dallin Lowder (D)

Department of Medicine, Baylor College of Medicine, Houston, Texas.

Collin McColl (C)

Department of Medicine, Baylor College of Medicine, Houston, Texas.

Patricia Castro (P)

Department of Pathology, Baylor College of Medicine, Houston, Texas.
Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.

Ryan Carelli (R)

Avera Institute for Human Genetics, Sioux Falls, South Dakota.

Elisa Benedetti (E)

Avera Institute for Human Genetics, Sioux Falls, South Dakota.

Jenny Deng (J)

Department of Medicine, Baylor College of Medicine, Houston, Texas.

Matthew Robertson (M)

Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.

Sylvan C Baca (SC)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.

Connor Bell (C)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.

Heather M McClure (HM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.

Talal El Zarif (T)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.

Matthew P Davidsohn (MP)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.

Gitanjali Lakshminarayanan (G)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.

Kinza Rizwan (K)

Department of Medicine, Baylor College of Medicine, Houston, Texas.

Darlene G Skapura (DG)

Department of Medicine, Baylor College of Medicine, Houston, Texas.

Sandra L Grimm (SL)

Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.

Christel M Davis (CM)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.

Erik A Ehli (EA)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.

Kaitlin M Kelleher (KM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Ji-Heui Seo (JH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.

Nicholas Mitsiades (N)

Department of Medicine, Baylor College of Medicine, Houston, Texas.
Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

Cristian Coarfa (C)

Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

Mark M Pomerantz (MM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.

Massimo Loda (M)

Avera Institute for Human Genetics, Sioux Falls, South Dakota.

Michael Ittmann (M)

Department of Pathology, Baylor College of Medicine, Houston, Texas.
Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.

Matthew L Freedman (ML)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.

Salma Kaochar (S)

Department of Medicine, Baylor College of Medicine, Houston, Texas.
Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH